SERA
Bearish signalScored 2026-09-11 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Sera Prognostics, Inc.
- Nom
- Sera Prognostics, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $78.1M
- Employés
- 72
- PDG
- Zhenya Lindgardt
- Site web
- https://www.sera.com
- Marché
- APYXATOSCGTXHURALUCDONCY
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 27 161 titres (~54 322,00 $ US)
- Insiders
- Lindgardt Zhenya
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$79,563
Avg sell (VWAP, 90d window) $2.01 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-10
- Last synced
-
2026-09-16 10:10:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-12 | Inglis Tiffany Eul Davis | Sell · S | 8,024 | $2.03 | $16,289 | Form 4 |
| 2026-09-10 | Anderson Dyaarl Lee Jr. | Sell · S | 1,800 | $2.00 | $3,600 | Form 4 |
| 2026-09-10 | Inglis Tiffany Eul Davis | Sell · S | 486 | $2.00 | $972 | Form 4 |
| 2026-09-10 | Jackson Benjamin | Sell · S | 2,190 | $2.00 | $4,380 | Form 4 |
| 2026-09-10 | Lindgardt Zhenya | Sell · S | 7,022 | $2.00 | $14,044 | Form 4 |
| 2026-09-08 | Lindgardt Zhenya | Sell · S | 20,139 | $2.00 | $40,278 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-09-11 Drivers: fundamentals. Moteurs : fondamentaux.
SERA presents a deeply concerning financial profile with critical liquidity (score: 35) and deteriorating fundamentals (score: 15), marked by -394% net margins and extreme cash burn with no credible path to…
The first sentence of the analysis written for SERA on 2026-09-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Bearish signal
Drivers: fundamentals. Moteurs : fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 1.69 · operating margin -45067% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -102.5% | -6.5% | 31.4% | 28.0% | 54.9% | |
| Ebit Margin | -39406.2% | -42688.3% | -11825.8% | -16464.6% | -41784.1% | |
| Ebitda Margin | -38245.7% | -41606.5% | -11531.7% | -16182.5% | -40980.5% | |
| Operating Profit Margin | -45066.7% | -47577.9% | -13013.4% | -17034.3% | -43164.6% | |
| Pretax Profit Margin | -39417.3% | -42724.7% | -11843.8% | -16487.3% | -42693.9% | |
| Continuous Operations Profit Margin | -39417.3% | -42724.7% | -11843.8% | -16487.3% | -42693.9% | |
| Net Profit Margin | -39417.3% | -42724.7% | -11843.8% | -16487.3% | -42693.9% | |
| Bottom Line Profit Margin | -39417.3% | -42724.7% | -11843.8% | -16487.3% | -42693.9% | |
| Current Ratio | 1.686 | 1.922 | 2.510 | 5.800 | 13.108 | |
| Quick Ratio | 1.686 | 1.922 | 2.510 | 5.800 | 13.108 | |
| Solvency Ratio | -1.168 | -1.294 | -1.398 | -2.498 | -4.058 | |
| Cash Ratio | 0.163 | 0.163 | 0.159 | 1.923 | 7.007 | |
| Price To Earnings Ratio | -4.403 | -8.222 | -5.155 | -0.881 | -5.822 | |
| Price To Earnings Growth Ratio | 0.136 | 0.561 | 0.273 | -0.042 | 6.928 | |
| Forward Price To Earnings Growth Ratio | 0.136 | 0.561 | 0.273 | -0.042 | 6.928 | |
| Price To Earnings Diluted Ratio | -4.403 | -8.222 | -5.155 | -0.881 | -5.822 | |
| Price To Earnings Diluted Growth Ratio | 0.136 | 0.561 | 0.273 | -0.042 | 6.928 | |
| Price To Book Ratio | 1.865 | 5.646 | 2.659 | 0.394 | 1.526 | |
| Price To Sales Ratio | 1,735.841 | 3,505.162 | 609.738 | 145.480 | 2,578.271 | |
| Price To Free Cash Flow Ratio | -5.336 | -17.652 | -6.830 | -1.101 | -6.418 | |
| Price To Operating Cash Flow Ratio | -5.487 | -19.022 | -6.863 | -1.127 | -6.683 | |
| Debt To Assets Ratio | 0.023 | 0.012 | 0.019 | 0.024 | 0.001 | |
| Debt To Equity Ratio | 0.031 | 0.018 | 0.026 | 0.029 | 0.001 | |
| Debt To Capital Ratio | 0.030 | 0.017 | 0.026 | 0.028 | 0.001 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.352 | 1.518 | 1.360 | 1.176 | 1.061 | |
| Working Capital Turnover Ratio | 0.004 | 0.003 | 0.005 | 0.003 | 0.002 | |
| Operating Cash Flow Ratio | -1.059 | -0.573 | -1.112 | -2.227 | -3.761 | |
| Operating Cash Flow Sales Ratio | -316.333 | -184.273 | -88.850 | -129.142 | -385.805 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.028 | 1.078 | 1.005 | 1.023 | 1.041 | |
| Debt Service Coverage Ratio | -2,816.273 | -1,144.179 | -641.582 | -710.967 | -45.046 | |
| Interest Coverage Ratio | -4,056.000 | -1,308.393 | -724.018 | -748.393 | -47.446 | |
| Short Term Operating Cash Flow Coverage Ratio | -12,811.500 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -10.955 | -16.892 | -14.633 | -12.225 | -247.156 | |
| Capital Expenditure Coverage Ratio | -35.293 | -12.887 | -212.406 | -43.755 | -24.261 | |
| Dividend Paid And Capex Coverage Ratio | -35.293 | -12.887 | -212.406 | -43.755 | -24.261 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -4.487 | -8.325 | -5.230 | -0.275 | -4.542 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -102.5% | ▼-96.0% | ▼-103.5% |
| Ebit Margin | -39406.2% | ▲3282.1% | ▼-8972.4% |
| Ebitda Margin | -38245.7% | ▲3360.8% | ▼-8536.3% |
| Operating Profit Margin | -45066.7% | ▲2511.3% | ▼-11895.3% |
| Pretax Profit Margin | -39417.3% | ▲3307.4% | ▼-8783.9% |
| Continuous Operations Profit Margin | -39417.3% | ▲3307.4% | ▼-8783.9% |
| Net Profit Margin | -39417.3% | ▲3307.4% | ▼-8783.9% |
| Bottom Line Profit Margin | -39417.3% | ▲3307.4% | ▼-8783.9% |
| Current Ratio | 1.685 | ▼-0.236 | ▼-3.320 |
| Quick Ratio | 1.685 | ▼-0.236 | ▼-3.320 |
| Solvency Ratio | -1.168 | ▲0.126 | ▲0.915 |
| Cash Ratio | 0.163 | ▼-0.000 | ▼-1.720 |
| Price To Earnings Ratio | -4.403 | ▲3.819 | ▲0.494 |
| Price To Earnings Growth Ratio | 0.136 | ▼-0.425 | ▼-1.435 |
| Forward Price To Earnings Growth Ratio | 0.136 | ▼-0.425 | ▼-1.435 |
| Price To Earnings Diluted Ratio | -4.403 | ▲3.819 | ▲0.494 |
| Price To Earnings Diluted Growth Ratio | 0.136 | ▼-0.425 | ▼-1.435 |
| Price To Book Ratio | 1.865 | ▼-3.781 | ▼-0.553 |
| Price To Sales Ratio | 1735.841 | ▼-1769.321 | ▲20.943 |
| Price To Free Cash Flow Ratio | -5.336 | ▲12.316 | ▲2.131 |
| Price To Operating Cash Flow Ratio | -5.487 | ▲13.534 | ▲2.349 |
| Debt To Assets Ratio | 0.023 | ▲0.011 | ▲0.007 |
| Debt To Equity Ratio | 0.031 | ▲0.013 | ▲0.010 |
| Debt To Capital Ratio | 0.030 | ▲0.013 | ▲0.010 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.352 | ▼-0.167 | ▲0.058 |
| Working Capital Turnover Ratio | 0.004 | ▲0.002 | ▲0.001 |
| Operating Cash Flow Ratio | -1.059 | ▼-0.486 | ▲0.687 |
| Operating Cash Flow Sales Ratio | -316.333 | ▼-132.061 | ▼-95.453 |
| Free Cash Flow Operating Cash Flow Ratio | 1.028 | ▼-0.049 | ▼-0.007 |
| Debt Service Coverage Ratio | -2816.273 | ▼-1672.094 | ▼-1744.664 |
| Interest Coverage Ratio | -4056.000 | ▼-2747.607 | ▼-2679.150 |
| Short Term Operating Cash Flow Coverage Ratio | -12811.500 | ▼-12811.500 | ▼-10249.200 |
| Operating Cash Flow Coverage Ratio | -10.955 | ▲5.937 | ▲49.417 |
| Capital Expenditure Coverage Ratio | -35.293 | ▼-22.406 | ▲30.427 |
| Dividend Paid And Capex Coverage Ratio | -35.293 | ▼-22.406 | ▲30.427 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -4.487 | ▲3.838 | ▲0.085 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $140.6M | $269.9M | $186.6M | $39.0M | $211.4M | |
| Enterprise value | $139.0M | $266.7M | $184.6M | $11.9M | $152.6M | |
| EV / Sales | 1716.03x | 3463.56x | 603.13x | 44.56x | 1861.15x | |
| EV / Op. cash flow | -5.42x | -18.80x | -6.79x | -0.34x | -4.82x | |
| EV / Free cash flow | -5.28x | -17.44x | -6.76x | -0.34x | -4.63x | |
| EV / EBITDA | -4.49x | -8.32x | -5.23x | -0.28x | -4.54x | |
| Net debt / EBITDA | 0.05x | 0.10x | 0.06x | 0.62x | 1.75x | |
| Current ratio | 1.69x | 1.92x | 2.51x | 5.80x | 13.11x | |
| Income quality | 0.80x | 0.43x | 0.75x | 0.78x | 0.90x | |
| Graham net-net | $0 | $1 | $1 | $2 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.1% | 100.2% | 100.1% | 102.2% | |
| Working capital | $16.6M | $22.8M | $36.9M | $74.6M | $101.8M | |
| Invested capital | $21.0M | $25.7M | $40.1M | $77.6M | $103.6M | |
| Return on assets | -31.3% | -45.3% | -38.0% | -38.0% | -23.8% | |
| Operating ROA | -41.8% | -43.6% | -37.6% | -34.7% | -43.7% | |
| Return on tangible assets | -31.6% | -46.0% | -38.0% | -38.0% | -23.8% | |
| Return on equity | -42.3% | -68.8% | -51.7% | -44.7% | -25.3% | |
| Return on invested capital | -47.0% | -75.3% | -55.3% | -44.9% | -25.5% | |
| Return on capital employed | -47.0% | -76.6% | -56.1% | -45.3% | -25.5% | |
| Earnings yield | -22.7% | -12.2% | -19.4% | -113.3% | -16.6% | |
| Free cash flow yield | -18.7% | -5.7% | -14.6% | -90.8% | -15.6% | |
| Capex / Op. cash flow | -2.8% | -7.8% | -0.5% | -2.3% | -4.1% | |
| Capex / Depreciation | 77.2% | 132.2% | 14.2% | 104.6% | 197.9% | |
| Capex / Sales | 896.3% | 1429.9% | 41.8% | 295.1% | 1590.2% | |
| SG&A / Sales | 28703.7% | 28441.6% | 8069.3% | 11747.4% | 29781.7% | |
| R&D / Sales | 16260.5% | 19129.9% | 4975.5% | 5314.9% | 13437.8% | |
| Stock comp / Sales | 6308.6% | 9107.8% | 1723.2% | 1886.2% | 3817.1% | |
| Intangibles / Total assets | 0.9% | 1.4% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 54d | 161d | 13682d | 8326d | 13990d | |
| Days payables outstanding | 1918d | 8764d | 1818d | 2928d | 11808d | |
| Operating cycle | 54d | 161d | 13682d | 8326d | 13990d | |
| Cash conversion cycle | -1864d | -8603d | 11863d | 5398d | 2182d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-47.9%EV / Sales ▼-50.5%EV / EBITDA ▲+46.1%EV / Op. cash flow ▲+13.371Earnings yield ▼-0.105
Profitability
Return on equity ▲+0.265Return on assets ▲+0.140Return on invested capital ▲+0.284Return on capital employed ▲+0.297Operating ROA ▲+0.018Income quality ▲+0.371Tax burden 0.000
Efficiency
Days sales outstanding ▼-107.095Days payables outstanding ▼-6845.976Operating cycle ▼-107.095Cash conversion cycle ▲+6738.881Capex / Sales ▼-5.336R&D / Sales ▼-28.694
Balance-sheet strength
Current ratio ▼-0.236Net debt / EBITDA ▼-0.048Working capital ▼-6248000.000Invested capital ▼-4665000.000Intangibles / Total assets ▼-0.005
Change over 5 years
Valuation
Market cap ▼-33.5%EV / Sales ▼-7.8%EV / EBITDA ▲+1.2%EV / Op. cash flow ▼-0.601Earnings yield ▼-0.061
Profitability
Return on equity ▼-0.171Return on assets ▼-0.075Return on invested capital ▼-0.214Return on capital employed ▼-0.214Operating ROA ▲+0.019Income quality ▼-0.101Tax burden 0.000
Efficiency
Days sales outstanding ▼-13936.109Days payables outstanding ▼-9889.768Operating cycle ▼-13936.109Cash conversion cycle ▼-4046.341Capex / Sales ▼-6.939R&D / Sales ▲+28.227
Balance-sheet strength
Current ratio ▼-11.422Net debt / EBITDA ▼-1.698Working capital ▼-85258000.000Invested capital ▼-82570000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-08-25 1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It. Dr. Thaïs Aliabadi, a board-certified OB-GYN and co-host of the SHE MD podcast, makes the case that preterm birth risk is personal, knowable between weeks 18 and 21 of pregnancy, and worth a direct conversation with your doctor. She points to a simple blood test, the PreTRM® Test from Sera Prognostics, and PRIME trial results showing early, low-cost intervention can cut the earliest preterm births by more than half.
- 2026-08-19 SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026. Mr. Gleason brings more than 25 years of healthcare, diagnostics, and capital markets experience to Sera.
- 2026-08-12 Sera Prognostics Q2 Earnings Call Highlights Sera Prognostics NASDAQ: SERA reported modest second-quarter revenue while outlining progress in payer engagement, Illinois Medicaid policy, clinical evidence and European regulatory preparations for its PreTRM Test-guided care platform.
- 2026-08-12 Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript Sera Prognostics, Inc. (SERA) Q2 2026 Earnings Call Transcript
- 2026-08-12 Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.16 per share a year ago.
- 2026-08-12 SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS SALT LAKE CITY, Aug. 12, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2026. Key Second Quarter and Recent Highlights: Advanced Commercial Adoption Strategy with Fourth Partnership Program Launch: In August 2026, we launched fourth partnership program, expanding implementation of PreTRM® Test-guided care through a state-based initiative with a national payer.
- 2026-07-29 SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026 SALT LAKE CITY, July 29, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report second quarter fiscal year 2026 financial results on Wednesday August 12, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.
- 2026-07-09 PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE -- Study Highlights Screening Efficiency and Potential Cost Savings in a Large Underserved Population -- SALT LAKE CITY, July 9, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced publication of a new subgroup analysis from the PRIME randomized controlled trial. The analysis demonstrated that PreTRM® Test-guided care in first-time pregnancies significantly improved neonatal outcomes, including a 22% reduction in neonatal intensive care unit (NICU) admissions.
- 2026-06-30 SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS SALT LAKE CITY, June 30, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Mark Capone will join its Board of Directors, effective July 1, 2026. Mr. Capone is a seasoned healthcare executive with more than 40 years of leadership experience across the diagnostics and life sciences sectors, including extensive service on private and public company boards and committees.
- 2026-06-24 SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH SALT LAKE CITY, June 24, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced its participation in a multi-institutional research program that was awarded up to $10.4 million by the Advanced Research Projects Agency for Health (ARPA-H) to develop a novel point-of-care diagnostic test designed to improve the safety of labor and delivery. The award, part of ARPA-H''s Making Obstetrics Care Smart (MOCS) program, supports a collaboration led by researchers at the University of California San Diego (UC San Diego), alongside Sera Prognostics and Allegro MicroSystems.